2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)2109 - North Ryde - Macquarie University Hospital (WITHDRAWN)2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (WITHDRAWN)

3000 - Melbourne - Peter MacCallum Cancer Centre (WITHDRAWN)3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)

4215 - Southport - Tasman Oncology (WITHDRAWN)4655 - Urraween - Cancer Care Service, Hervey Bay Hospital (WITHDRAWN)4670 - Bundaberg - Bundaberg Hospital, Genesis Cancer Care (WITHDRAWN)

NA

NCT05413421

An Open-Label, Phase 1/1b Study of ORIC-944 As a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer (ORIC-944-01)

NCT05393791

ANZadapt: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer

NCT05367440

A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

NCT04947189

4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer

NCT04925648

PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction (PICASSO)

NCT04597411

AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy (PSMA-617-100)

NCT04464226

An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored Studies

SA5037 - Glandore - Ashford Cancer Centre (COMPLETED)

NCT04221542

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT02960022

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study (9785-CL-0123)

2076 - Wahroonga - Sydney Adventist Hospital (COMPLETED)2485 - Tweed Heads - The Tweed Hospital (COMPLETED)2640 - Albury - Border Medical Oncology Research Unit (COMPLETED)

3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (COMPLETED)

QLD4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)

NCT02861573

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

ACTRN12625000224426

Not Applicable

Salvage sTereotactic Ablative radiotherapy for patients with Recurrent prostate cancer With Androgen suppression and Rectal Spacer, assessing toxicity and quality of life (STARWARS)

ACTRN12624000582550

Evaluating the efficacy of bipolar androgen therapy in extending metastasis-free survival in patients with M0 castrate-resistant prostate cancer with prostate specific antigen progression but not radiological or clinical progression on darolutamide (WOMBAT) - ANZUP 2201

ACTRN12624000110583

Not Applicable

SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (SOCRATES-PILOT)

ACTRN12623000160639

A Randomized, Open-Label, Phase 2 Study of Darolutamide as Single Agent or in Combination with EPI-7386 as a Neoadjuvant Treatment for Patients Undergoing Prostatectomy for Localized Prostate Cancer (DaSCENT)

ACTRN12619000567123

EnzAdapt: Feasibility, acceptability and safety of adaptive dosing of enzalutamide in men with metastatic castrate-resistant prostate cancer

NCT05551117

A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors (Tamarack)

NCT05288166

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer (CYCLONE-3)

NCT05252390

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01)

NCT05252364

A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer (HP518-CS-001)

NCT03170960

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (XL184-021)

NCT03124615

Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate Cancer

androgen axis	100%
AR	86%
CYP17A1	54%
PARP	16%
oestrogen axis	14%
CYP11A1	8%
PD-1/PD-L1	8%
STEAP1	5%
LHRH	5%
PARP1-selective	5%
PSMA	5%
CDK4	5%
CDK6	5%
GnRH	5%
PD-1	5%
KIT	5%
VEGF	5%
EZH2	3%
KLK2	3%
PRC2 complex	3%
BCR-ABL1	3%
PDGFRA	3%
SRC	3%
YES1	3%
HIF2a	3%
TIGIT	3%
HMG-CoA reductase	3%
antiandrogen,AR NTD	3%
B7H3	3%
BET	3%
AXL	3%
MET	3%
PD-L1	3%
RET	3%
ROS1	3%
VEGFR	3%
VEGFR2	3%

ARTICANZ - Beta (ver 0.9)

Search results

target/androgen-axis

Filters